



TEXAS MEDICAID VENDOR DRUG PROGRAM DRUG UTILIZATION REVIEW BOARD MEETING - RETROSPECTIVE DRUG USE PROPOSALS

Friday, April 28, 2023

<http://www.txvendordrug.com/>

REVISED CRITERIA

1. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anti-Cholinergic Drugs
2. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anti-Inflammatory Drugs
3. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Beta2 Adrenergic Drugs (Long-Acting)
4. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Beta2 Adrenergic Drugs (Short-Acting)
5. Anti-Depressants, Oral (Other)
6. Anti-Depressants, Selective Serotonin Reuptake Inhibitors



**REVISED CRITERIA: AEROSOLIZED AGENTS - METERED-DOSE
INHALERS (MDIS): ANTI-CHOLINERGIC DRUGS**

REVISED CRITERIA: AEROSOLIZED AGENTS - METERED-DOSE INHALERS (MDIS): ANTI- CHOLINERGIC DRUGS

- **Dosage**

- Removed statement about removal of Utibron Neohaler® (indacaterol/glycopyrrolate) and Seebri Neohaler® (glycopyrrolate) from market
 - Products have been removed from criteria set
- Table 2. Maximum Recommended Adult Anticholinergic Metered-Dose Inhaler Daily Dose – Combination Therapy
 - Added Breztri Aerosphere® (budesonide, glycopyrrolate, formoterol fumarate)
- Table 4. Days' Supply for Anticholinergic Metered-Dose Inhaler Products – Monotherapy
 - Removed institutional only package sizes

REVISED CRITERIA: AEROSOLIZED AGENTS - METERED-DOSE INHALERS (MDIS): ANTI- CHOLINERGIC DRUGS

- **Dosage**

- Table 5. Days' Supply for Anticholinergic Metered-Dose Inhaler Products – Combination Therapy
 - Added package size and days' supply for Breztri Aerosphere® (budesonide, glycopyrrolate, formoterol fumarate)
- Table 6. Drug-Drug Interactions with Inhaled Combination Anticholinergics
 - Removed discontinued products
 - Updated drug interaction resource to Clinical Pharmacology
- References updated throughout criteria set



**REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE
INHALERS (MDIS): ANTI-INFLAMMATORY DRUGS**

REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE INHALERS (MDIS): ANTI- INFLAMMATORY DRUGS

- **Dosage**

- Updated wording for Symbicort® (budesonide/formoterol) indication for ease of reading
- Table 2. Maximum Adult Daily Recommended Doses for ICS as Combination Therapy for Asthma and COPD
 - Updated column order
 - Added that generic formulations are available for Symbicort® (budesonide/formoterol), Advair HFA® (fluticasone/ salmeterol), Advair Diskus® (fluticasone/ salmeterol), and Breo Ellipta® (fluticasone/ vilanterol)
 - Added Breztri Aerosphere® (budesonide/ glycopyrrolate/ formoterol fumarate)

REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE INHALERS (MDIS): ANTI- INFLAMMATORY DRUGS

- **Dosage**

- Table 3. Maximum Recommended Pediatric Doses for ICS as Monotherapy in Asthma
 - Added generic formulation for Flovent HFA® (fluticasone)
- Table 4. Maximum Pediatric Recommended Doses for ICS as Combination Therapy for Asthma
 - Added that generic formulations are available for Symbicort® (budesonide/ formoterol), Advair HFA® (fluticasone/ salmeterol), and Advair Diskus® (fluticasone/ salmeterol)

REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE INHALERS (MDIS): ANTI-INFLAMMATORY DRUGS

• Duration of Therapy

- Updated information about combined formoterol and budesonide therapy for maintenance and rescue therapy for patients with asthma from the Global Strategy for Asthma Management and Prevention guidelines
- Table 5. Days' Supply+ for Available ICS as Monotherapy When Maximum Doses are Utilized (Adults and Children)
 - Updated product package sizes
 - Removed products that are available as institutional only packaging
 - Added Breztri Aerosphere® (budesonide/ glycopyrrolate/ formoterol fumarate)

• Duplicative Therapy

- Added updated guideline information

REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE INHALERS (MDIS): ANTI-INFLAMMATORY DRUGS

- **Drug Interactions**

- Table 7. ICS Drug-Drug Interactions
 - Updated drug interaction resource to Clinical Pharmacology
- References updated throughout criteria set



**Revised criteria: Aerosolized Agents – Metered-dose Inhalers
(MDIS): Beta2 Adrenergic Drugs (long-acting)**

REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE INHALERS (MDIS): BETA2 ADRENERGIC DRUGS (LONG-ACTING)

- **Dosage**

- Updated information about combined formoterol and budesonide therapy for maintenance and rescue therapy for patients with asthma from the Global Strategy for Asthma Management and Prevention guidelines
- Removed references to Utibron Neohaler® (indacaterol/glycopyrrolate), Seebri Neohaler® (glycopyrrolate), and Arcapta Neohaler® (indacaterol) as these products have been discontinued

REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE INHALERS (MDIS): BETA2 ADRENERGIC DRUGS (LONG-ACTING)

- **Dosage**

- Table 2. LABA Maximum Daily Dosage Recommendations in Adults with Asthma and COPD: Combination Therapy
 - Updated column order
 - Added that generic formulations are available for Symbicort® (budesonide/ formoterol), Advair HFA® (fluticasone/ salmeterol), Advair Diskus® (fluticasone/ salmeterol), and Breo Ellipta® (fluticasone/ vilanterol)
 - Added Breztri Aerosphere® (budesonide/ glycopyrrolate/ formoterol fumarate)
- Removed references to indacaterol as no products are currently on the market

REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE INHALERS (MDIS): BETA2 ADRENERGIC DRUGS (LONG-ACTING)

- **Duration of Therapy**

- Updated guideline recommendations about the use of formoterol and budesonide as maintenance and rescue therapy for patients with asthma
- Added statement that long acting Beta₂ agonists (LABAs) should generally only be used for maintenance therapy, and removed paragraph detailing indication of maintenance therapy for each LABA

REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE INHALERS (MDIS): BETA2 ADRENERGIC DRUGS (LONG-ACTING)

- **Duration of Therapy**

- Table 6. Days' Supply for Available Long-Acting Beta2-Adrenergic Metered Dose Inhalers (Adult and Pediatric Patients) – Combination Therapy

- Removed pack sizes for institutional use only
- Added Breztri Aerosphere® (budesonide/ glycopyrrolate/ formoterol fumarate)

- **Drug-Drug Interactions**

- Table 7. Key Drug-Drug Interactions for Inhaled LABAs and Combination Products

- Updated drug interaction resource to Clinical Pharmacology

- References Updated throughout criteria set



**Revised criteria: Aerosolized Agents – Metered-Dose Inhalers
(MDIS): Beta2 Adrenergic Drugs (Short-Acting)**

REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE INHALERS (MDIS): BETA2 ADRENERGIC DRUGS (SHORT-ACTING)

- **Dosage**
- Table 1. Maximum Adult Daily Dose for Inhalational Beta₂-Adrenergic Agents (Short-Acting) – Monotherapy
 - Updated column order
 - Removed ProAir HFA® (albuterol) as product has been discontinued
 - Added exercise induced bronchospasm (EIB) indication to table for albuterol products
- Removed references to ProAir HFA® (albuterol)
- Table 3. Maximum Recommended Pediatric Daily Dose for Inhalational Beta2-Adrenergic Agents (Short-Acting) – Monotherapy
 - Removed ProAir HFA® (albuterol) as product has been discontinued
 - Added exercise induced bronchospasm (EIB) indication to table for albuterol products

REVISED CRITERIA: AEROSOLIZED AGENTS – METERED-DOSE INHALERS (MDIS): BETA2 ADRENERGIC DRUGS (SHORT-ACTING)

- **Dosage**
- Table 4. Days' Supply for Available Short-Acting Beta₂-Adrenergic Agent Metered-Dose Inhalers (Adult and Pediatric Patients) – Monotherapy
 - Removed ProAir HFA® (albuterol) and updated with generic formulation
 - Removed institutional only package sizes
- **Drug-Drug Interactions**
- Table 6. Inhaled Short-Acting Beta2-Adrenergic Agents Drug-Drug Interactions
 - Updated drug interaction resource to Clinical Pharmacology
- References Updated throughout criteria set



ANTI-DEPRESSANTS, ORAL (OTHER)

ANTI-DEPRESSANTS, ORAL (OTHER)

- **Dosage**

- Table 1. Adult and Elderly Maximum Recommended Antidepressant Dosages (Monotherapy) - Tricyclic Antidepressants

- Removed brand name Elavil® (amitriptyline) as only generic is manufactured at this time
- Updated amitriptyline dosing to indicate dosing should be divided throughout the day
- Updated amoxapine dosing to reflect product labeling
- Separated imipramine hydrochloride and imipramine pamoate for clarification of available formulations
- Removed brand name Norpramin® (desipramine) as only generic is manufactured at this time
- Updated protriptyline dosing to reflect product labeling

ANTI-DEPRESSANTS, ORAL (OTHER)

- **Dosage**
- Table 2. Adult and Elderly Maximum Recommended Antidepressant Dosages (Monotherapy) - Tetracyclic Antidepressants
 - Removed maprotiline as product is no longer on the market
- Table 3. Adult and Elderly Maximum Recommended Antidepressant Dosages (Monotherapy) - Monoamine Oxidase Inhibitors
 - Updated indication of phenelzine to reflect product labeling
 - Updated maximum dose of EMSAM® (selegiline) transdermal patch to reflect product labeling

ANTI-DEPRESSANTS, ORAL (OTHER)

- **Dosage**

- Table 4. Adult and Elderly Maximum Recommended Antidepressant Dosages (Monotherapy) – Serotonin and Norepinephrine Reuptake Inhibitors

- Removed brand name Khedezla® (desvenlafaxine) as product is no longer on the market

- Table 6. Adult and Elderly Maximum Recommended Antidepressant Dosages (Monotherapy) – Miscellaneous Agents

- Removed Oleptro (trazodone) as this formulation is no longer on the market

ANTI-DEPRESSANTS, ORAL (OTHER)

- **Dosage**

- Table 8. Pediatric Maximum Recommended Antidepressant Drug Dosages (Monotherapy) – Tricyclic Antidepressants

- Updated amitriptyline dosing to reflect product labeling
- Removed imipramine pamoate formulations, added language clarifying imipramine pamoate is not approved for pediatric use

- Table 10. Pediatric Maximum Recommended Antidepressant Drug Dosages (Monotherapy) – Serotonin and Norepinephrine Reuptake Inhibitors

- Removed brand name Khedezla® (desvenlafaxine) as product is no longer on the market

ANTI-DEPRESSANTS, ORAL (OTHER)

- **Renal Impairment**

- Table 13. Select non-SSRI Antidepressant Dosage Modifications in Renal Impairment – Monoamine Oxidase Inhibitors

- Removed tranylcypromine to reflect product labeling

- **Drug-Drug Interactions**

- Table 16. Major Drug-Drug Interactions for Non-SSRI Antidepressant Drugs

- Updated drug interaction resource to Clinical Pharmacology

- References Updated throughout criteria set



**ANTI-DEPRESSANTS, SELECTIVE SEROTONIN REUPTAKE
INHIBITORS**

ANTI-DEPRESSANTS, SELECTIVE SEROTONIN REUPTAKE INHIBITORS

- **Dosage**

- Updated paragraph describing FDA approved indications of SSRIs to reflect product labeling

- Table 1. Oral SSRI Medications - Adult Maximum Recommended Dosages – Monotherapy

- Added citalopram 30 mg capsule
- Separated fluoxetine dosing by indication for ease of reading
- Removed Pexeva® (paroxetine) 40 mg due to product no longer being on the market
- Separated Paxil® (paroxetine) dosing based off maximum dosing and indications
- Decreased maximum dose of Paxil CR® (paroxetine) to reflect available formulations

ANTI-DEPRESSANTS, SELECTIVE SEROTONIN REUPTAKE INHIBITORS

- **Dosage**
- Table 3. Recommended SSRI Antidepressant Drug Dosages for Pediatric Patients – Monotherapy
 - Updated column order
 - Added citalopram 30 mg capsules
 - Added major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) dosing
- **Drug-Drug Interactions**
- Table 6. Major Drug-Drug Interactions for SSRI Antidepressant Drugs 1
 - Updated drug interaction resource to Clinical Pharmacology
- References Updated throughout criteria set



TEXAS MEDICAID VENDOR DRUG PROGRAM DRUG UTILIZATION REVIEW BOARD MEETING - RETROSPECTIVE DRUG USE PROPOSALS

Friday, April 28, 2023

<http://www.txvendordrug.com/>